NSE: CONCORDBIO · 29 October 2026
- Concord Biotech has fallen 10.56% over 2 trading sessions; today's move is -3.04%.
- Concord Biotech reported a 25% year-on-year increase in consolidated revenue to ₹309.1 crore for the quarter ended September 30, 2026, while net profit grew 10% to ₹69.6 crore. Gross profit margins softened to 76.2% from 80.2% a year ago due to higher input costs and changes in product mix, and the company also announced the launch of its new dermatology division, Inspira.
- Trading volume was 1.57 times the 20-day average daily volume.
Concord Biotech share price: 10.56% decline over 2 trading sessions
Concord Biotech Ltd. fell 3.04% today, closing at ₹1,230.00 compared to its previous close of ₹1,268.50. The stock opened at ₹1,264.50 and moved within a day's range of ₹1,227.00 and ₹1,280.00.
While broader benchmarks gained ground, with the Nifty rising 1.05% and the Nifty Pharma sector index advancing 0.64%, Concord Biotech underperformed its sector peers. The stock has experienced a broader pullback, recording a 5-day return of -3.20% and a 20-day return of -12.81%, reflecting persistent downward pressure over the preceding weeks.
The downward price action follows the company's recent second-quarter earnings release for the period ended September 30, 2026, which reported revenue of ₹309.1 crore and a net profit of ₹69.6 crore alongside margin compression due to higher input costs and product mix changes. Additionally, the company fixed November 4, 2026, as the record date for its upcoming 1:1 bonus share issue.
1.73 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 1.10 lakh shares (1.57 times). The five-day average daily volume was 1.83 lakh shares. Separately, the NSE report for 28 October 2026 showed 1.30 lakh shares delivered, representing 34.17% of that day’s traded volume. The same report recorded 41,457 trades.
The stock declined 3.04% on above-average volume, continuing a weak 20-day trend where shares have fallen 12.81%. While recent Q2 earnings and upcoming bonus share record dates provide broader corporate context, today's move reflects ongoing selling pressure and sector divergence.
Latest Company Developments
Concord Biotech reported a 25% year-on-year increase in consolidated revenue to ₹309.1 crore for the quarter ended September 30, 2026, while net profit grew 10% to ₹69.6 crore. Gross profit margins softened to 76.2% from 80.2% a year ago due to higher input costs and changes in product mix, and the company also announced the launch of its new dermatology division, Inspira.
Quarterly earnings and margin metrics directly influence fundamental valuations and near-term market sentiment toward the stock.
Following earlier board approvals, the company formally notified the stock exchanges that Wednesday, November 4, 2026, has been designated as the record date for determining shareholders eligible to receive bonus equity shares in the ratio of 1:1. Thursday, November 5, 2026, serves as the deemed date of allotment.
Bonus issues alter the share capital structure and influence retail liquidity around the record date.
Concord Biotech Limited has informed the Exchange that Record date for the purpose of Bonus is 04-Nov-2026.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Research & Brokerage Views
Citi reinitiated coverage on Concord Biotech with a Neutral rating, pointing to a growth moderation in the active pharmaceutical ingredients segment.
Historical Bulk / Block Deals
What to Watch Next
- Trading activity and liquidity shifts leading up to the November 4, 2026 record date for the 1:1 bonus issue
- Execution and adoption metrics for the newly launched Inspira dermatology division
- Sustained delivery percentage trends relative to the 34.17% recorded on October 28, 2026
- Export and formulation revenue growth trajectory in subsequent quarters
Other Dated Coverage
- Concord Biotech Share Price Falls 8.17% Intraday, Closes 7.77% Lower | 28 October 2026 — 28 October 2026
- Concord Biotech Share Price Today: Rises 11.88% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech reported a 25% year-on-year increase in consolidated revenue to ₹309.1 crore for the quarter ended September 30, 2026, while net profit grew 10% to ₹69.6 crore. Gross profit margins softened to 76.2% from 80.2% a year ago due to higher input costs and changes in product mix, and the company also announced the launch of its new dermatology division, Inspira.
How strong was Concord Biotech’s trading volume?
1.73 lakh shares traded, 1.57 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.